Navigation Links
Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
Date:10/23/2007

of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. The most common adverse reactions are vomiting (9%), hypokalemia (7%), hyperglycemia (7%), convulsions (6%), and mental impairments (6%). Do not administer to patients with known hypersensitivity to sodium phenylacetate or sodium benzoate. Acute symptomatic hyperammonemia should be treated as life-threatening. Uncontrolled hyperammonemia can result in brain damage or death. Dialysis may be required, preferably hemodialysis, to remove a large burden of ammonia. Administration must be through a central line; use of a peripheral line may cause burns. Do not administer undiluted product. Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses should not be administered. Use caution when administering to patients with hepatic or renal insufficiency. AMMONUL(R) may cause nausea and vomiting. An antiemetic may be administered during infusion. See the prescribing information for a complete listing of warnings, precautions, and drug interactions.

About BUPHENYL(R)

BUPHENYL(R) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). BUPHENYL(R) should not be administered to patients with known hypersensitivity to sodium phenylbutyrate or any component of this preparation. The most common adverse reactions associated with BUPHENYL(R) were amenorrhea dysfunction, decreased appetite, body odor (probably caused by its metabolite phenylacetate) and bad taste or taste aversion. Patients with urea cycle disorders should not take valproic acid, haloperidol, or steroids as these drugs have been reported to increase blood ammonia levels, and probenecid may affect the kidneys' excretion. Use with great care, if at all, in patients wi
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... and consumables to the medical, research and veterinary markets, ... Chief Executive Officer, will present at the CL King ... Tuesday, September 9, 2014 at 12:30 p.m. ET. The ... Hotel in New York City . ...
(Date:8/29/2014)... 2014 Pixcelldata, the innovative Irish ... announced a major new deal with Dutch based eX-Path, ... expert, Dr. Marius Nap . The ... Congress of Pathology which is taking placing between August ... London where Pixcelldata will demonstrate its ...
(Date:8/29/2014)... Mass. , Aug. 29, ... PHG AEX: ... the  European Society of Cardiology ... is highlighting the full range of its cardiology solutions serving ... care continuum from prevention and diagnosis, ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 3Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 4Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 5
... 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... Stock Exchange (the "NYSE") has notified the Company that the ... requires a minimum average closing price of $1.00 per share ... the Company has six months from receipt of the notice ...
... Business Journal recently announced that eCardio Diagnostics ( www.ecardio.com ) ... included a distinguished list of 100 of the fastest growing ... ranked No. 17 with a two-year growth of 146.37%. This ... prestigious award. "There were so many inspiring companies ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2eCardio Among Honorees of the Houston Business Journal's Fast 100 List for Second Consecutive Year 2
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 The ... facilities in New Jersey and even in the U.S. ... that takes inches off of patients’ waists with deep-tissue ... cells in small sections, Vanquish is more inclusive to ... Patients lay comfortably under panels about one inch ...
(Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
(Date:8/30/2014)... Beach, Calif. (PRWEB) August 30, 2014 Insomnia ... Francis helps listeners understand how they unknowingly developed insomnia and ... have restful nights during. Tune in to the show ... The show airs live on August 30, and will ... more information on programming, go to DrCarolFrancisTalkRadio.com. , ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... result of a car accident," said one of two ... muscle strain in her shoulder and neck area. She ... invented reduced pain and pressure, assisting in comfort and ... the patent-pending PILLOW CRADLE to support the head, neck ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's ... Labor Day discount on all SEO services. While working ... services related to internet marketing. Their dedicated team of ... do have a deep understanding for their specialization. This ... and since the inception, they have worked with over ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
... difficult for doctors to tell whether a patient with ... inflammation, which can be treated with medicine. A new ... a U-M-led study. Ultrasound elasticity imaging, or UEI, ... inflammation and fibrosis, allowing patients to receive more appropriate ...
... State University of New York has received two grants ... of Health (NIH) to support neuroscience and pediatric pharmacology ... collaborative research network of SUNY,s four academic health centers ... both grants will be headquartered at SUNY Downstate Medical ...
... who experience new onset breast tenderness after starting combination ... cancer compared to women who don,t experience breast tenderness, ... Center has shown. One reason for this may be ... new onset tenderness was much more pronounced after initiation ...
... more effective than the current standard treatment. This is ... treatments, described by Thilo Schwandner and colleagues in the ... Dtsch Arztebl Int 2011; 108[39]: 653-60). In ... The problem is often caused by weakness of the ...
... 1982, alone in a laboratory, chemist Dan Shechtman looked ... He had discovered quasicrystals. But his groundbreaking findings ... years. On October 5, 2011, Shechtman received ... to stand by his research? What drove the men ...
... News) -- Teen drivers are 50 percent more likely to crash ... are after driving for a full year, according to a study ... drivers are nearly twice as likely to crash in the first ... the study found. However, parents can help teens prevent accidents ...
Cached Medicine News:Health News:Imaging technology might help doctors determine best treatment for Crohn's disease patients 2Health News:SUNY receives $4.3 million for research in neuroscience, pediatric pharmacology and vision 2Health News:SUNY receives $4.3 million for research in neuroscience, pediatric pharmacology and vision 3Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 2Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 3Health News:How and why did 2011 Nobel winner Dan Shechtman persist despite rejection? 2Health News:Teen Crash Risk High in First Month of Driving, Study Finds 2